Drug intelligence / Profile preview

NTX-400

Development stage: Preclinical
Lead developer: Nectin Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NTX-400 is a preclinical-stage monoclonal antibody developed by Nectin Therapeutics that targets TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT is an inhibitory immune checkpoint receptor expressed on various immune cells, including T cells and Natural Killer (NK) cells. By binding to TIGIT, NTX-400 prevents its interaction with ligands such as CD155 (PVR), thereby relieving immune suppression and enhancing the body's anti-tumor immune response. The drug is currently being developed for the treatment of advanced solid tumors.

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on NTX-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX-400.

Explore the full profile